Tumor models to investigate the therapeutic efficiency of immunomodulators.

James E Talmadge, B. F. Lenz, M. S. Collins, K. A. Uithoven, M. A. Schneider, J. S. Adams, J. W. Pearson, W. J. Agee, R. E. Fox, R. K. Oldham

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalBehring Institute Mitteilungen
Issue number74
StatePublished - May 1 1984

Fingerprint

Immunologic Factors
Immunotherapy
Tumors
Immunomodulation
Clinical Protocols
Tumor Burden
Neoplasms
Theoretical Models
Observation
Clinical Trials
Neoplasm Metastasis
Animals
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Talmadge, J. E., Lenz, B. F., Collins, M. S., Uithoven, K. A., Schneider, M. A., Adams, J. S., ... Oldham, R. K. (1984). Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Institute Mitteilungen, (74), 219-229.

Tumor models to investigate the therapeutic efficiency of immunomodulators. / Talmadge, James E; Lenz, B. F.; Collins, M. S.; Uithoven, K. A.; Schneider, M. A.; Adams, J. S.; Pearson, J. W.; Agee, W. J.; Fox, R. E.; Oldham, R. K.

In: Behring Institute Mitteilungen, No. 74, 01.05.1984, p. 219-229.

Research output: Contribution to journalArticle

Talmadge, JE, Lenz, BF, Collins, MS, Uithoven, KA, Schneider, MA, Adams, JS, Pearson, JW, Agee, WJ, Fox, RE & Oldham, RK 1984, 'Tumor models to investigate the therapeutic efficiency of immunomodulators.', Behring Institute Mitteilungen, no. 74, pp. 219-229.
Talmadge JE, Lenz BF, Collins MS, Uithoven KA, Schneider MA, Adams JS et al. Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Institute Mitteilungen. 1984 May 1;(74):219-229.
Talmadge, James E ; Lenz, B. F. ; Collins, M. S. ; Uithoven, K. A. ; Schneider, M. A. ; Adams, J. S. ; Pearson, J. W. ; Agee, W. J. ; Fox, R. E. ; Oldham, R. K. / Tumor models to investigate the therapeutic efficiency of immunomodulators. In: Behring Institute Mitteilungen. 1984 ; No. 74. pp. 219-229.
@article{9171076b2c454a71ac43383a43e27a02,
title = "Tumor models to investigate the therapeutic efficiency of immunomodulators.",
abstract = "The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.",
author = "Talmadge, {James E} and Lenz, {B. F.} and Collins, {M. S.} and Uithoven, {K. A.} and Schneider, {M. A.} and Adams, {J. S.} and Pearson, {J. W.} and Agee, {W. J.} and Fox, {R. E.} and Oldham, {R. K.}",
year = "1984",
month = "5",
day = "1",
language = "English (US)",
pages = "219--229",
journal = "Behring Institute Mitteilungen",
issn = "0301-0457",
publisher = "Behringwerke AG",
number = "74",

}

TY - JOUR

T1 - Tumor models to investigate the therapeutic efficiency of immunomodulators.

AU - Talmadge, James E

AU - Lenz, B. F.

AU - Collins, M. S.

AU - Uithoven, K. A.

AU - Schneider, M. A.

AU - Adams, J. S.

AU - Pearson, J. W.

AU - Agee, W. J.

AU - Fox, R. E.

AU - Oldham, R. K.

PY - 1984/5/1

Y1 - 1984/5/1

N2 - The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.

AB - The development of successful approaches to immunotherapy is dependent on the proper consideration of the pathobiology of metastasis and a better understanding of the principles of biological response modification. Immunomodulation as a therapeutic modality has not proven notably effective in animals with preexistent palpable disease, an observation in agreement with the results from clinical protocols. Therefore, rather than developing experimental immunotherapy models of immunoprophylaxis or models with minimal tumor burden, we believe it more appropriate to develop models based on preexistent metastatic disease in a tumor-conditioned host. The most rigorous test of a biological response modifier's efficiency prior to clinical trials will be provided from immunotherapeutic trials of palpable autochthonous tumors.

UR - http://www.scopus.com/inward/record.url?scp=0021421273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021421273&partnerID=8YFLogxK

M3 - Article

SP - 219

EP - 229

JO - Behring Institute Mitteilungen

JF - Behring Institute Mitteilungen

SN - 0301-0457

IS - 74

ER -